BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9723634)

  • 1. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure.
    Luzier AB; Forrest A; Adelman M; Hawari FI; Schentag JJ; Izzo JL
    Am J Cardiol; 1998 Aug; 82(4):465-9. PubMed ID: 9723634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
    Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW;
    Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia.
    Adigun AQ; Ajayi AA
    Eur J Heart Fail; 2001 Jun; 3(3):359-63. PubMed ID: 11378008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacogenomic control of angiotensin converting enzyme gene I/D polymorphism predominant risk factor of development of chronic heart failure and target of enalapril treatment].
    Tepliakov AT; Shilov SN; Berezikova EN; Efremov AV; Safronov ID; Pustovetova MG; Maianskaia SD; Torim IuIu; Karpov RS
    Kardiologiia; 2013; 53(3):9-14. PubMed ID: 23548421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure.
    McDermott MM; Lee P; Mehta S; Gheorghiade M
    Clin Cardiol; 1998 Apr; 21(4):261-8. PubMed ID: 9562936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology.
    Gambassi G; Lapane KL; Sgadari A; Carbonin P; Gatsonis C; Lipsitz LA; Mor V; Bernabei R
    Arch Intern Med; 2000 Jan; 160(1):53-60. PubMed ID: 10632305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE-inhibitor therapy at relatively high doses and risk of renal worsening in chronic heart failure.
    De Vecchis R; Di Biase G; Ariano C; Cioppa C; Giasi A; Ciccarelli A; Pucciarelli A; Cantatrione S
    Arq Bras Cardiol; 2011 Dec; 97(6):507-16. PubMed ID: 22001954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of pharmacologic treatment of congestive heart failure in elderly nursing home residents and related issues: a review of the literature.
    Litaker JR; Chou JY
    Clin Ther; 2003 Jul; 25(7):1918-35. PubMed ID: 12946542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community pharmacist outreach program directed at physicians treating congestive heart failure.
    Turner CJ; Parfrey P; Ryan K; Miller R; Brown A
    Am J Health Syst Pharm; 2000 Apr; 57(8):747-52. PubMed ID: 10786260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure.
    Tu K; Mamdani M; Kopp A; Lee D
    Am J Cardiol; 2005 Jan; 95(2):283-6. PubMed ID: 15642572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
    Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM
    Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure.
    Pacher R; Stanek B; Globits S; Berger R; Hülsmann M; Wutte M; Frey B; Schuller M; Hartter E; Ogris E
    Eur Heart J; 1996 Aug; 17(8):1223-32. PubMed ID: 8869864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acetylsalicylic acid antagonism vs ACE inhibitor in congestive heart failure as shown by a diminished respiratory and exercise capacity].
    Guazzi M; Lauri G; Melzi G; Cattadori G; Agostoni P
    Cardiologia; 1996 Jun; 41(6):527-33. PubMed ID: 8766415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure.
    Chen YT; Wang Y; Radford MJ; Krumholz HM
    Am Heart J; 2001 Mar; 141(3):410-7. PubMed ID: 11231438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure.
    Brunner-La Rocca HP; Weilenmann D; Kiowski W; Maly FE; Candinas R; Follath F
    Am Heart J; 1999 Oct; 138(4 Pt 1):654-62. PubMed ID: 10502210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
    Tang WH; Vagelos RH; Yee YG; Fowler MB
    Am Heart J; 2004 Nov; 148(5):889-94. PubMed ID: 15523323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of digoxin on time domain measures of heart rate variability in patients with stable chronic cardiac failure: withdrawal and comparison group studies.
    Flapan AD; Goodfield NE; Wright RA; Francis CM; Neilson JM
    Int J Cardiol; 1997 Mar; 59(1):29-36. PubMed ID: 9080023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge.
    McDonald K; Ledwidge M; Cahill J; Kelly J; Quigley P; Maurer B; Begley F; Ryder M; Travers B; Timmons L; Burke T
    Eur J Heart Fail; 2001 Mar; 3(2):209-15. PubMed ID: 11246059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisinopril: a review of its use in congestive heart failure.
    Simpson K; Jarvis B
    Drugs; 2000 May; 59(5):1149-67. PubMed ID: 10852646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.